ZA200808596B - Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors - Google Patents

Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors

Info

Publication number
ZA200808596B
ZA200808596B ZA200808596A ZA200808596A ZA200808596B ZA 200808596 B ZA200808596 B ZA 200808596B ZA 200808596 A ZA200808596 A ZA 200808596A ZA 200808596 A ZA200808596 A ZA 200808596A ZA 200808596 B ZA200808596 B ZA 200808596B
Authority
ZA
South Africa
Prior art keywords
receptors
preparation
inhibit vanilloid
ureas
indazolyl
Prior art date
Application number
ZA200808596A
Other languages
English (en)
Inventor
Kirill A Lukin
Hsu Margaret Chi-Ping
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA200808596B publication Critical patent/ZA200808596B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA200808596A 2006-04-14 2008-10-08 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors ZA200808596B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
ZA200808596B true ZA200808596B (en) 2010-03-31

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808596A ZA200808596B (en) 2006-04-14 2008-10-08 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (VR1) receptors

Country Status (21)

Country Link
US (2) US7847104B2 (xx)
EP (1) EP2012779B1 (xx)
JP (1) JP2009533474A (xx)
KR (2) KR20110017464A (xx)
CN (4) CN101466374B (xx)
AU (1) AU2007238019B2 (xx)
BR (1) BRPI0709963A2 (xx)
CA (1) CA2647261A1 (xx)
CR (1) CR10357A (xx)
EC (1) ECSP088878A (xx)
ES (1) ES2385404T3 (xx)
HK (1) HK1123725A1 (xx)
MX (1) MX2008013205A (xx)
MY (1) MY145334A (xx)
NO (1) NO20084698L (xx)
NZ (1) NZ571705A (xx)
RU (1) RU2446161C2 (xx)
TW (1) TW200815362A (xx)
UA (1) UA94100C2 (xx)
WO (1) WO2007121339A2 (xx)
ZA (1) ZA200808596B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
US20140275505A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
AU2017295745A1 (en) 2016-07-12 2019-01-31 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pest control agents
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (xx) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPH09504004A (ja) 1993-08-20 1997-04-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用アミドおよび尿素誘導体
WO2003035065A1 (en) * 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1499599A1 (en) 2002-04-26 2005-01-26 Pharmacia & Upjohn Company LLC Substituted pyrazine derivatives
EP2246333B1 (en) * 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2004275694B2 (en) * 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
EP1940843A4 (en) * 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
WO2007056075A2 (en) * 2005-11-02 2007-05-18 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
CN101316818B (zh) * 2005-11-30 2011-08-31 弗·哈夫曼-拉罗切有限公司 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类

Also Published As

Publication number Publication date
US20070244178A1 (en) 2007-10-18
AU2007238019B2 (en) 2013-03-14
MX2008013205A (es) 2008-10-22
TW200815362A (en) 2008-04-01
NZ571705A (en) 2012-03-30
US7847104B2 (en) 2010-12-07
US8519186B2 (en) 2013-08-27
RU2008144961A (ru) 2010-05-20
ECSP088878A (es) 2008-12-30
KR20090003335A (ko) 2009-01-09
RU2446161C2 (ru) 2012-03-27
NO20084698L (no) 2008-11-07
US20110040102A1 (en) 2011-02-17
HK1123725A1 (en) 2009-06-26
EP2012779A4 (en) 2010-11-24
EP2012779A2 (en) 2009-01-14
CA2647261A1 (en) 2007-10-25
WO2007121339A2 (en) 2007-10-25
CN102140081A (zh) 2011-08-03
CN101466374A (zh) 2009-06-24
CR10357A (es) 2008-12-11
UA94100C2 (ru) 2011-04-11
ES2385404T3 (es) 2012-07-24
CN102321025A (zh) 2012-01-18
EP2012779B1 (en) 2012-05-16
CN101466374B (zh) 2012-03-21
CN102775350A (zh) 2012-11-14
KR20110017464A (ko) 2011-02-21
AU2007238019A1 (en) 2007-10-25
WO2007121339A3 (en) 2008-10-02
JP2009533474A (ja) 2009-09-17
KR101118932B1 (ko) 2012-02-27
BRPI0709963A2 (pt) 2011-08-02
MY145334A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
EP2012778A4 (en) VANILLOID RECEPTOR (VR1) SUBType 1 ANTAGONISTS AND USES THEREOF
IL183321A0 (en) Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
HK1157757A1 (zh) 製備環巴胺類似物化合物的方法
HK1123725A1 (en) Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors
PL1806330T3 (pl) Sposób wytwarzania 1-butenu z technicznych mieszanin węglowodorów C<sub>4</sub>
ZA200707614B (en) Process for the polymerizatio of olefins
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
PL1743882T3 (pl) Sposób do produkcji izocyjanianów
SI1797037T1 (sl) Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida
HK1201822A1 (en) Process for the preparation of 5,6-dihydro-1h-pyridin-2-one compounds 56--1h--2-
ZA200903533B (en) Process for the preparation of rosuvastatin
IL187208A0 (en) Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
PL2222678T3 (pl) Sposoby wytwarzania związków morfinanowych (+)-'nal'
PT1748990E (pt) Processo para a preparação de telmisartan
IL191753A0 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
IL206469A0 (en) Process for the preparation of fipronil and analogues thereof
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
IL177315A0 (en) Process for the preparation of substituted triazole compounds
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
IL187426A0 (en) Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
EG25547A (en) Process for the preparation of amines
HK1144682A1 (en) Process for the preparation of alkyl 3,3-dialkoxypropionates 33-
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
IL201661A0 (en) Thia(dia) zoles as fast dissociating dopamine 2 receptor antagonists
IL206570A (en) 4,3-Dihydro Compound-1 h- Isoquinoline is converted into 3 positions, process for preparation and use